Immuron to launch PROIBS® in the United States
Immuron secures exclusive U.S. rights to distribute PROIBS, expanding its digestive health portfolio into a $4.16 billion supplement market.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immuron (IMRN) announced on 4 September 2026 an exclusive U.S. distribution agreement with Calmino group AB for digestive health product PROIBS®.
Immuron previously launched PROIBS® in Australia in FY26 and now targets a segment of the U.S. digestive/gut health supplement market, valued at $4.16 billion. PROIBS® is a European-certified medical device for abdominal pain, bloating and unsettled bowel movements, containing AVH200® from Aloe barbadensis Mill to support the intestinal mucosal barrier.
Calmino’s usability study of 1,003 users found PROIBS® was helpful for 94%, with 91% reporting improved daily life and 98% willing to recommend it.
Positive
- Exclusive U.S. distribution agreement for PROIBS® with Calmino group AB
- $4.16 billion U.S. digestive/gut health supplement market targeted in part
- Usability study: PROIBS® helpful for 94% of 1,003 users, with 91% reporting improved daily life
- 98% of users would recommend PROIBS®, indicating strong user satisfaction
Negative
- None.
News Explained
Immuron says it has executed an exclusive U.S. distribution agreement for PROIBS®, moving the disclosure beyond a planned launch to a completed agreement; the release describes a commercial arrangement, not a change to existing holders’ ownership.
Details
Market move: IMRN +62.16% in the Sep 4 session. PROIBS distribution partnership
On Sep 4, the day this news came out, IMRN closed 62.16% above the previous close. Argus tracked a peak move of +62.5% during that session. Our momentum scanner recorded 126 alerts for this stock that day. Relative volume reached 8108.1x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 4 session.
Key Figures
- U.S. digestive health market
- $4.16 billion
- Overall U.S. digestive/gut health supplement market
- Usability study users
- 1,003 users
- PROIBS usability study
- Users finding PROIBS helpful
- 94%
- Usability study
- Daily-life improvement
- 91%
- Usability study users
- Would recommend PROIBS
- 98%
- Usability study users
Historical Context
-
Record FY26 sales and improved cash position were followed by a 1.29% decline.
-
CEO webinar presentation announcement was followed by a 6.61% decline.
-
FY26 Travelan sales growth was followed by a 5.04% decline.
-
Pullan Consulting engagement for IMM-529 partnering was followed by a 1.82% gain.
-
Research report raised its price target from $3.90 to $4.00; shares declined 5.29%.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
medical device regulatory
intestinal mucosal barrier medical
usability study technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MELBOURNE, Australia, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to announce that it has executed an exclusive distribution agreement for PROIBS® in the United States with Calmino group AB. Immuron launched PROIBS® in Australia during FY26.
The overall U.S. digestive/gut health supplement market is valued at
Flavio Palumbo, Chief Commercial Officer said “Following the rapid growth of Travelan® sales in the US, we have developed a commercial growth strategy to bring a portfolio of innovative digestive health products to market. PROIBS® is a great opportunity to further expand our digestive health portfolio by providing our customers with a proven premium product that delivers improvement in daily life. With PROIBS®, we are able to provide an innovative and European certified medical device. The product has been on the Swedish pharmacy market for more than a decade. Because it is backed by science and recommended by physicians and dietitians, we can promote PROIBS® with absolute confidence. We are looking forward to offering a solution that truly improves the livability of the affected people.”
Tobias Kisker, CEO and founder of Calmino group AB, commented “We are immensely proud to further expand our collaboration with Immuron. What started with PROIBS® in Australia is now developing into a partnership across two continents, with the United States becoming our next important market together. We look forward to building on the strong relationship we have established with Immuron.”
This release has been authorised by the directors of Immuron Limited.
COMPANY CONTACT:
Steven Lydeamore
Chief Executive Officer
steve@immuron.com
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
For more information visit: https://www.immuron.com.au/ and https://www.travelan.com
Subscribe to Immuron’s InvestorHub: Here
About Calmino group AB
Calmino group AB is a Swedish life science company founded in 2003 and based at Sahlgrenska Science Park in Gothenburg, Sweden. The company develops and commercializes science-driven products within digestive health. Its lead product, PROIBS®, has been available in European markets for more than a decade and is currently distributed internationally.
FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Immuron (IMRN) announce about PROIBS in the United States?
Immuron announced it has executed an exclusive distribution agreement with Calmino group AB to distribute PROIBS® in the United States. The company plans to use PROIBS® to expand its digestive health portfolio following its prior launch of the product in Australia during FY26.
What is PROIBS and what conditions is it intended to help with?
PROIBS® is described as a medical device used to help manage abdominal pain, bloating and unsettled bowel movements, including diarrhoea and constipation. It contains AVH200®, derived from Aloe barbadensis Mill, with gel-forming components that support the intestinal mucosal barrier and is suitable for long-term use.
How large is the U.S. digestive health supplement market Immuron is targeting with PROIBS (IMRN)?
The overall U.S. digestive/gut health supplement market is valued at $4.16 billion, based on Mordor Intelligence data. Immuron is targeting a subset of this market with PROIBS®, aiming to broaden its presence in digestive health products.
What were the results of the PROIBS usability study cited by Immuron (IMRN)?
Calmino group AB conducted a usability study among 1,003 users of PROIBS®. PROIBS® was helpful for 94% of participants, 91% experienced an improvement in daily life, and 98% said they would recommend the product to someone else.
Who is Calmino group AB in Immuron’s PROIBS U.S. distribution deal?
Calmino group AB is described as a science-driven, innovative company and the developer of PROIBS®. Under the new arrangement, Calmino grants Immuron exclusive distribution rights for PROIBS® in the United States, extending a collaboration that began with the product’s launch in Australia.
How does PROIBS fit into Immuron’s broader digestive health strategy?
Immuron’s Chief Commercial Officer said that, after rapid growth of Travelan® sales in the U.S., the company developed a commercial growth strategy to build a portfolio of innovative digestive health products. PROIBS® is presented as an opportunity to expand this portfolio with a proven, European-certified medical device.